HK1223795A1 - 拉喹莫德響應性的基因表達生物標誌物 - Google Patents
拉喹莫德響應性的基因表達生物標誌物Info
- Publication number
- HK1223795A1 HK1223795A1 HK16112324.4A HK16112324A HK1223795A1 HK 1223795 A1 HK1223795 A1 HK 1223795A1 HK 16112324 A HK16112324 A HK 16112324A HK 1223795 A1 HK1223795 A1 HK 1223795A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- laquinimod
- responsiveness
- gene expression
- expression biomarkers
- biomarkers
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title 1
- 230000014509 gene expression Effects 0.000 title 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title 1
- 229960004577 laquinimod Drugs 0.000 title 1
- 230000004043 responsiveness Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361877210P | 2013-09-12 | 2013-09-12 | |
US201461972782P | 2014-03-31 | 2014-03-31 | |
PCT/US2014/055502 WO2015038963A1 (en) | 2013-09-12 | 2014-09-12 | Gene expression biomarkers of laquinimod responsiveness |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1223795A1 true HK1223795A1 (zh) | 2017-08-11 |
Family
ID=52666348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16112324.4A HK1223795A1 (zh) | 2013-09-12 | 2016-10-26 | 拉喹莫德響應性的基因表達生物標誌物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20160201132A1 (zh) |
EP (1) | EP3043647A4 (zh) |
JP (1) | JP2016530892A (zh) |
CA (1) | CA2922958A1 (zh) |
HK (1) | HK1223795A1 (zh) |
IL (1) | IL244402A0 (zh) |
MX (1) | MX2016002987A (zh) |
WO (1) | WO2015038963A1 (zh) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
JP5986745B2 (ja) | 2008-07-15 | 2016-09-06 | アカデミア シニカAcademia Sinica | Ptfe様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法 |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
AU2013306098A1 (en) | 2012-08-18 | 2015-02-12 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
US10086054B2 (en) | 2013-06-26 | 2018-10-02 | Academia Sinica | RM2 antigens and use thereof |
EP3013347B1 (en) | 2013-06-27 | 2019-12-11 | Academia Sinica | Glycan conjugates and use thereof |
CN105682666B (zh) | 2013-09-06 | 2021-06-01 | 中央研究院 | 使用醣脂激活人类iNKT细胞 |
TW201620939A (zh) | 2014-01-16 | 2016-06-16 | 中央研究院 | 治療及檢測癌症之組合物及方法 |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
TWI797430B (zh) | 2014-03-27 | 2023-04-01 | 中央研究院 | 反應性標記化合物及其用途 |
AU2015267045B2 (en) | 2014-05-27 | 2021-02-25 | Academia Sinica | Anti-HER2 glycoantibodies and uses thereof |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
KR20170003720A (ko) | 2014-05-27 | 2017-01-09 | 아카데미아 시니카 | 항-cd20 글리코항체 및 이의 용도 |
CA2950423A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
EP3154582A4 (en) | 2014-05-28 | 2018-01-10 | Academia Sinica | Anti-tnf-alpha glycoantibodies and uses thereof |
WO2016040369A2 (en) | 2014-09-08 | 2016-03-17 | Academia Sinica | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
EP3789766A1 (en) | 2015-01-24 | 2021-03-10 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
WO2017100796A1 (en) * | 2015-12-11 | 2017-06-15 | SINACA, Academia | Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers |
JP2019515876A (ja) | 2016-03-08 | 2019-06-13 | アカデミア シニカAcademia Sinica | N−グリカンおよびそのアレイのモジュール合成のための方法 |
EP3481963A1 (en) * | 2016-07-08 | 2019-05-15 | Genentech, Inc. | Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene. |
CN109963868B (zh) | 2016-08-22 | 2023-11-14 | 醣基生医股份有限公司 | 抗体、结合片段及使用方法 |
US20190336585A1 (en) * | 2018-05-03 | 2019-11-07 | John Lawrence Mee | Method for sustainable human cognitive enhancement |
US20190359985A1 (en) * | 2018-05-22 | 2019-11-28 | John Lawrence Mee | Adjustable method for sustainable human cognitive enhancement |
US20190390193A1 (en) * | 2018-06-23 | 2019-12-26 | John Lawrence Mee | Reversible method for sustainable human cognitive enhancement |
EP3586866A1 (en) * | 2018-06-28 | 2020-01-01 | Universität Zürich | Immunodominant proteins and fragments in multiple sclerosis |
WO2020163794A1 (en) * | 2019-02-08 | 2020-08-13 | Msdx, Inc. | Detection of brain-derived debris in recirculating phagocytes |
US11271935B2 (en) | 2020-07-30 | 2022-03-08 | Bank Of America Corporation | Blind authenticator |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2392352B1 (en) * | 2009-01-28 | 2017-10-25 | Korea Research Institute of Bioscience and Biotechnology | Cd93 or use of soluble fragment thereof |
EP2414542B1 (en) * | 2009-03-30 | 2017-08-30 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Methods of predicting clinical course and treating multiple sclerosis |
US20130029916A1 (en) * | 2011-07-28 | 2013-01-31 | Yossi Gilgun | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate |
-
2014
- 2014-09-12 US US14/914,523 patent/US20160201132A1/en not_active Abandoned
- 2014-09-12 WO PCT/US2014/055502 patent/WO2015038963A1/en active Application Filing
- 2014-09-12 MX MX2016002987A patent/MX2016002987A/es unknown
- 2014-09-12 EP EP14844641.2A patent/EP3043647A4/en not_active Withdrawn
- 2014-09-12 CA CA2922958A patent/CA2922958A1/en not_active Abandoned
- 2014-09-12 JP JP2016542831A patent/JP2016530892A/ja active Pending
-
2016
- 2016-03-02 IL IL244402A patent/IL244402A0/en unknown
- 2016-10-26 HK HK16112324.4A patent/HK1223795A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3043647A4 (en) | 2017-05-10 |
MX2016002987A (es) | 2016-10-07 |
EP3043647A1 (en) | 2016-07-20 |
US20160201132A1 (en) | 2016-07-14 |
WO2015038963A1 (en) | 2015-03-19 |
JP2016530892A (ja) | 2016-10-06 |
IL244402A0 (en) | 2016-04-21 |
CA2922958A1 (en) | 2015-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1223795A1 (zh) | 拉喹莫德響應性的基因表達生物標誌物 | |
HK1222466A1 (zh) | 遺傳變異分析 | |
IL244791A0 (en) | Methods for modifying a host cell | |
SI3068881T1 (sl) | Z nukleazo posredovano uravnavanje izražanja genov | |
LT3080100T (lt) | Lizinui specifinės demetilazės-1 inhibitoriai | |
SG11201510747RA (en) | Method for increasing expression of rna-encoded proteins | |
HK1218014A1 (zh) | 用以間接判定參考間距的方法 | |
GB201316880D0 (en) | Controlling disclosure of structured data | |
HK1222339A1 (zh) | 金屬-β-內酰胺酶的抑制劑 | |
IL240763B (en) | The halopyrazoles as thrombin inhibitors | |
SG11201601919SA (en) | Method of friction control | |
GB201313440D0 (en) | Characterization of rice | |
HK1221159A1 (zh) | 轉移抑制劑 | |
GB201709321D0 (en) | Improved method of data dependent control | |
GB2521478B (en) | Control of data provision | |
GB201312311D0 (en) | Uses of enzyme inhibitors | |
IL230063A0 (en) | A technique to control selection order | |
GB201308639D0 (en) | Biomarkers and uses of thereof | |
AU5220P (en) | Jewel of DesertTopaz Delosperma cooperi | |
GB201322036D0 (en) | New therapeutic uses of enzyme inhibitors | |
GB201313826D0 (en) | Predicting of physical training response | |
GB201310488D0 (en) | New therapeutic uses of enzyme inhibitors | |
GB201303264D0 (en) | Method of control |